Growth of basal cell carcinomas (BCCs) requires high levels of hedgehog (HH) signalling through the transcription factor GLI 1 . Although inhibitors of membrane protein smoothened (SMO) effectively suppress HH signalling, early tumour resistance illustrates the need for additional downstream targets for therapy 1-6 . Here we identify atypical protein kinase C i/l (aPKC-i/l) as a novel GLI regulator in mammals. aPKC-i/l and its polarity signalling partners 7 co-localize at the centrosome and form a complex with missing-inmetastasis (MIM), a scaffolding protein that potentiates HH signalling 8, 9 . Genetic or pharmacological loss of aPKC-i/l function blocks HH signalling and proliferation of BCC cells. Prkci is a HH target gene that forms a positive feedback loop with GLI and exists at increased levels in BCCs. Genome-wide transcriptional profiling shows that aPKC-i/l and SMO control the expression of similar genes in tumour cells. aPKC-i/l functions downstream of SMO to phosphorylate and activate GLI1, resulting in maximal DNA binding and transcriptional activation. Activated aPKC-i/l is upregulated in SMO-inhibitor-resistant tumours and targeting aPKC-i/l suppresses signalling and growth of resistant BCC cell lines. These results demonstrate that aPKC-i/l is critical for HH-dependent processes and implicates aPKC-i/l as a new, tumour-selective therapeutic target for the treatment of SMO-inhibitor-resistant cancers.
To identify new druggable targets in the HH pathway, we used the scaffold protein MIM, which potentiates GLI-dependent activation downstream of SMO (ref. 9) , as bait in a biased proteomics screen of factors involved in HH signalling and ciliogenesis. Two of the hits were polarity proteins not previously linked to the HH pathway: aPKC-i/l, a serine/threonine kinase, and PARD3, a scaffold protein and aPKC-i/ l substrate ( Supplementary Fig. 1a ). Reciprocal immunoprecipitation of aPKC-i/l and PARD3 pulled down MIM, suggesting a specific interaction ( Supplementary Fig. 1b ). Because MIM is a centrosomeassociated protein that promotes ciliogenesis 8 , we fractionated centrosomes and found that aPKC-i/l, along with PARD3 and PARD6A, co-fractionated and co-immunoprecipitated with MIM in c-tubulinpositive fractions that mark centrosomes ( Fig. 1a and Supplementary  Fig. 1c ). MIM partly co-localizes with aPKC-i/l-complex members at the basal body in dermal fibroblasts, keratinocytes and the wellcharacterized mouse BCC cell line ASZ001 10 (Fig. 1b) , where aPKCi/l and MIM interact through co-immunoprecipitation ( Fig. 1c ). Loss of aPKC-i/l or MIM protein suppressed HH signalling, because messenger RNA (mRNA) levels of the HH target gene Gli1 were reduced and ciliogenesis was inhibited ( Fig. 1d , e and Supplementary Fig. 1d, e ).
Because the kinase activity is necessary for many of the cellular functions of aPKC-i/l (refs 7, 11), we used a myristoylated aPKC peptide inhibitor (PSI) to suppress kinase activity 12 ( Supplementary  Fig. 1f ). PSI, but not a myristoylated scrambled peptide, inhibited HH signalling in BCC cells in a dose-dependent manner similar to the SMO antagonist cyclopamine ( Fig. 1f ). PSI, the pan-PKC inhibitor Go6983 and genetic loss of aPKC-i/l expression also resulted in dosedependent inhibition of cell growth in BCC cells, leading to cell death according to MTT assay ( Fig. 1g and Supplementary Fig. 1g , h). PSI inhibited BCC cell growth at a concentration similar to that of cyclopamine, with a half-maximal inhibitory concentration (IC 50 ) of 5 mM. Primary cilia were reduced by 50% in PSI-treated BCC cells ( Fig. 1e ), indicating that aPKC activity is critical to both HH signalling and ciliogenesis in BCC cells. Interestingly, PSI did not affect proliferation in several non-tumorigenic cells ( Supplementary Fig. 1i ). PSI specifically inhibited aPKC, because loss of aPKC-i/l in BCC cells in combination with PSI treatment possessed no additional activity to reduce levels of Gli1 or Prkci mRNA ( Supplementary Fig. 1j ).
To address whether the effects of aPKC-i/l on the HH pathway are direct, we assayed aPKC-i/l function in several nonpolar cell lines ( Supplementary Fig. 1k , l and data not shown). These cells maintained their primary cilia or developed more after loss of aPKC-i/l; however, aPKC-i/l removal still blocked HH activation, reducing target gene induction. We conclude that the effects of aPKC-i/l on HH signalling are cilia independent and are required for maximal sustained signalling.
aPKC-i/l is necessary for maximal HH signalling, and so we next investigated whether aPKC-i/l is overexpressed in BCCs. Indeed, Prkci expression, but not Prkcz expression, is specifically upregulated with Gli1 in BCC cells ( Fig. 2a ). Similar results are found using freshly isolated human BCCs compared with primary human keratinocytes ( Fig. 2b ). Immunohistochemical staining of human BCCs and normal skin with antibodies recognizing both total and activated aPKC (P-aPKC) show higher levels in invasive and nodular tumours, with P-aPKC showing greater overexpression ( Fig. 2c ). Loss of aPKC-i/l removes both aPKC and P-aPKC staining in primary mouse dermal cells, indicating the specificity of the antibody ( Supplementary Fig. 2 ).
Because aPKC-i/l and HH signalling are required for BCC cell growth, we then asked whether Prkci is a HH target gene. Activation of HH signalling in both polarized and non-polarized primary and immortalized cells using SHH-N ligand (the amino-terminal fragment of SHH) induces both Gli1 and Prkci transcripts, but not Prkcz (Fig. 2d ). Additionally, when we block HH signalling by treating BCC cells with cyclopamine, Gli1 and Prkci transcripts, but not Prkcz, are specifically suppressed ( Fig. 2g ). Three putative GLI1-binding sites 13 are present in the promoter region within 5 kilobases of the Prkci transcriptional start site in mice ( Fig. 2e ). Chromatin immunoprecipitation (ChIP) with BCC cells overexpressing FLAG:GLI1 enrich in regions containing the three GLI1-binding sites ( Fig. 2f ), indicating that Prkci is a direct target of GLI1. The first two GLI1-binding sites promote expression of luciferase when expressed in BCC cells, suggesting that these sites are functional ( Supplementary Fig. 3 ). In addition, expression of Pard6a (aPKC-i/l inhibitor) is reduced whereas Cdc42 (activator) is overexpressed in primary mouse BCC tumours 14 (Fig. 2h ). Because aPKC-i/l is typically found in an inhibited PARD6A complex, less PARD6A would result in excessive free and active aPKC-i/l whereas more CDC42 would activate any existing PARD6A-aPKC-i/l complexes. Interestingly, when HH signalling is inhibited with the SMO antagonist SANT-1, Pard6a transcript levels are increased and Cdc42 levels are decreased ( Fig. 2i ), further supporting the idea that HH signalling promotes aPKC-i/l activation. We conclude that aPKC-i/l is part of a HH-mediated positive feedback loop leading to its overexpression in human and mouse BCCs.
To gain insight into aPKC-i/l's mechanism of action, we determined whether aPKC-i/l-dependent genes in tumours differed from those regulated by SMO. We treated BCC cells with SANT-1 or PSI and performed 39-end polyadenylated RNA sequencing. We found that the expression level of 5,700 SANT-1-dependent and 4,762 PSI-dependent transcripts changed twofold or more when compared with a control (Fig. 3a) . Also, 4,325 transcripts overlapped between the inhibitor-treated data sets (P , 1.0 3 10 2300 ), with most transcripts being downregulated in both sets (Fig. 3b ). Gene ontology terms associated with commonly changed transcripts include cell cycle regulation, protein transport and localization, and cell division ( Fig. 3c ). Global transcript expression regardless of fold-change showed a strong positive correlation between drug treatments, with a Pearson LETTER RESEARCH correlation of 0.495. Comparison with previously published HHdependent data sets from mouse medulloblastomas/granular neural precursors or developing mouse limb bud 15, 16 reveals substantial overlap ( Supplementary Fig. 4a ). We found that 321 of the 1,077 GLI1binding sites found in medulloblastomas/granular neural precursors (P 5 1.36 3 10 211 ) and 41 of the 396 GLI3-binding sites identified in the developing limb bud (P 5 8.92 3 10 29 ) overlap with our commonly changed data set. Representative gene expression profiles among the data sets are displayed in a cluster heat map in Supplementary Fig. 4b . Validation of a subset of transcript expression levels using quantitative reverse-transcription PCR shows that the relative values from our data set closely mirror actual mRNA levels on drug treatment (Supplementary Fig. 4c, d) . These results indicate that aPKC-i/l and SMO regulate a common set of HH target genes in BCCs. The striking overlap of transcriptional targets suggested that aPKCi/l might regulate GLI transcription factors. To determine where aPKC-i/l acts, we added subthreshold concentrations of cyclopamine or PSI to BCC cells. We found that only cyclopamine outcompeted SAG-mediated activation ( Supplementary Fig. 5a ), indicating that aPKC-i/l functions downstream of SMO. Moreover, aPKC-i/l inhibition slightly increases rather than decreases GLI1 stability ( Supplementary Fig. 5b ), does not affect GLI2 or GLI3 processing ( Supplementary Fig. 5c ), and does not alter GLI1 nuclear localization ( Fig. 3d and Supplementary Fig. 5d ), suggesting that aPKC-i/l affects GLI activity. Intriguingly, loss of aPKC-i/l protein in mouse fibroblasts results in a GLI1 band with slightly smaller apparent molecular weight ( Supplementary Fig. 5e, f) . By contrast, loss of MIM, despite primary cilia defects that prevent substantial activation of the HH pathway 8 , have more aPKC-i/l protein and a GLI1 band with a slightly larger apparent molecular weight, suggesting aPKC-i/l modifies GLI1 post-translationally.
Consistent with the notion of aPKC-i/l-dependent alteration of GLI1 activity, aPKC-i/l and GLI1 form a complex as recombinant HIS:aPKC-i/l and in vitro-translated (IVT) human HA:GLI1 or HA:GLI1 zinc-finger co-immunoprecipitate ( Fig. 3e) . Purified aPKCi/l directly phosphorylates GLI1 in vitro (Fig. 3f) , with the majority of the phosphorylation occurring in the zinc-finger DNA-binding region of GLI1. Immunoprecipitation of endogenous GLI1 from BCC cells shows PSI-dependent phosphorylation at serine/threonine residues, further supporting an in vivo role for aPKC-i/l (Fig. 3g) .
PSI-treated IVT human GLI1:V5/HIS, where endogenous aPKC-i/l is inhibited in the reaction, significantly reduced binding to radiolabelled GLI1 target DNA in an electrophoretic mobility assay (Fig. 3h, i) . Addition of recombinant aPKC-i/l overcame the effects of PSI to rescue GLI1-dependent DNA binding, whereas the addition of heat-inactivated aPKC-i/l did not ( Supplementary Fig. 5g ), indicating that GLI1 phosphorylation by aPKC-i/l is necessary for maximal DNA binding. The phosphorylation state of GLI1 seems to be critical because higher concentrations of aPKC-i/l led to paradoxically decreased DNA binding ( Supplementary Fig. 5g ).
We performed a mutagenesis screen of the GLI1 DNA-binding domain to determine the site of aPKC-i/l phosphorylation and 
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found that residues Ser 243 and Thr 304 seem to mediate aPKC-i/l effects. Phosphomimetic GLI1 (GLI1 S243E,T304E ) bound to target DNA just as well as wild-type GLI1 did, whereas phosphodeficient GLI1 (GLI1 S243A,T304A ), which accumulates less aPKC-i/l phosphorylation ( Supplementary Fig. 5h ), has less DNA-binding ability (Fig. 3h, i) . Moreover, GLI1 S243E,T304E is less sensitive to PSI in BCC cells, suggesting that these sites are functional aPKC-i/l sites (Fig. 3j ). To confirm that aPKC-i/l regulates GLI binding in vivo, we performed ChIP of FLAG:GLI1 in BCC cells using GLI target genes 17, 18 . On all GLI1 targets assayed, PSI-treated tumour cells left GLI1 nuclear protein levels unchanged but reduced the association with chromatin ( Fig. 3d, k) . Non-HH target genes were left unchanged by PSI treatment. We conclude that aPKC-i/l regulates HH signalling by phosphorylating and activating GLI1 to increase its affinity for DNA, illustrating a rare instance where post-translational modification of a zinc-finger domain promotes DNA binding and transcriptional activity.
To explore whether aPKC inhibitors can be used successfully as a BCC therapeutic, we topically treated allografted BCC tumours 14 with PSI. This tumour model accurately describes human BCCs and has previously been used to validate HH pathway inhibitors now in clinical use 19 . In allografted BCCs, Gli1 mRNA decreased as the concentration of topical PSI was increased (Fig. 4a) . Also, tumour size was suppressed for intermediate concentrations of PSI, with no apparent acquired resistance ( Fig. 4b) . This compares favourably with treatment with intermediate concentrations of SMO antagonist itraconazole 19 or GLI2 inhibitor arsenic trioxide 20 (Fig. 4c ). Tumours lost their classical palisade patterning on PSI treatment, and apoptosis increased ( Supplementary Fig. 6 ). Cell proliferation was reduced along with GLI1 protein levels. Mice treated with topical or intraperitoneal PSI showed no apparent adverse effects ( Supplementary Fig. 7 ) except a mild hair cycling phenotype (not shown) suggesting that aPKC treatment is tumour selective.
Because aPKC-i/l acts downstream of SMO, we determined whether PSI could inhibit cell growth of SMO-resistant tumours. Following methods to generate resistant lines for other chemotherapeutics such as K-ras or B-raf 21 , we generated multiple independent BCC cell lines that were resistant to high levels of SANT-1. These SMO-resistant lines displayed increased expression of Prkci mRNA and protein, with varying levels of Gli1 mRNA ( Fig. 4d and Supplementary Fig. 8a) . Other HH target genes displayed differential expression patterns that followed Gli1 or Prkci mRNA levels, or were generally suppressed (Supplementary Fig. 8b ). We verified SMO resistance by treating the cells with high concentrations of structurally unrelated cyclopamine and found little effect on cell proliferation (Fig. 4e ). Treatment of these lines, or SANT-1-sensitive parental lines, with PSI drastically reduced cell proliferation, suggesting that active aPKC-i/l has a role in SMO-inhibitor-resistant human tumours. Comparison of SMO-inhibitor-sensitive and SMOinhibitor-resistant locally invasive human BCCs, several of which lacked SMO and SUFU mutations as well as GLI1/2 amplification (B. Yauch, personal communication), showed elevated levels of active aPKC-i/l in resistant tumours with polyclonal and monoclonal antibodies, corroborating the increase of active aPKC-i/l levels as a mode of resistance (Fig. 4f, g and Supplementary Fig. 8c, d) . Taken together, these data indicate that BCCs become dependent on aPKC-i/l to drive HH activation and tumour growth, and that suppression of aPKC-i/l activity is sufficient to prevent BCC progression in both SMO-sensitive and SMO-resistant lines. Our results highlight aPKC-i/l inhibition as a viable, tumour-selective alternative to SMO inhibitors to treat HH-dependent and SMO-resistant cancers.
METHODS SUMMARY
All mouse studies were approved by and conformed to the policies and regulations of the Institutional Animal Care and Use Committees at Stanford University and the Children's Hospital Oakland Research Institute. Ptch1 1/2 ;K14-creER2;p53 flox/flox mice were used to develop BCC tumours. Tumours were allografted as previously described 14 . Nine tumours from three mice were treated topically twice daily with 0.8 mg kg 21 PSI dissolved in DMSO for at least 32 days, with measurements on some tumours lasting 42 days. Ten tumours from three mice were treated with DMSO twice daily as a control. Mice were killed and tumours collected when tumour size exceeded the limit in our animal care guidelines. We measured the change in tumour size with callipers every three to four days. Pairwise comparisons between DMSO and PSI treatment were done using a two-sided unpaired t-test with GraphPad PRISM software.
The electrophoretic mobility shift assay was performed by incubation of 50 fmol double-stranded radio-labelled GLI1 oligonucleotides (59-AGCCCGGACCAC CCACGAGAA-39) in binding buffer (25 mM HEPES pH 7.5, 25 mM KCl, 2.5 mM MgCl 2 , 1 mM DTT, 10% glycerol, 25 mM poly(dI-dC) and 5 mM ZnSO 4 ) with IVT GLI1:V5/HIS, HA:GLI1, HA:GLI1 S243E,T304E or HA:GLI1 S243A,T304A lysate for 10 min at 25 uC. Unlabelled GLI1 oligonucleotides or GLI1 mutant oligonucleotides (2 pmol) (59-AGCCCGGAGGAGGCACGAGAA-39) were used as competition. Endogenous aPKC was inhibited in reticulocyte lysate with PSI during the translation reaction, and rescue was performed by adding recombinant HIS: aPKC-i/l for 15 min before addition of radio-labelled GLI1 oligonucleotides. Samples were resolved on 6% acrylamide gel, exposed to a phosphor screen (Molecular Dynamics) and imaged using a GE Typhoon 9410. 
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